RESUMO
Background Detection and quantification of anti-thyroid antibodies make it possible to confirm the diagnosis of thyroid dysfunction as well as its autoimmune origin and monitor thyroid damage in diabetic patients. The aim of this study is to determine the seroprevalence of anti-thyroid antibodies in hospitalized diabetic patients. Materials and methods This retrospective study focused on 91 diabetic patients hospitalized in the endocrinology department of Ibn Sina Hospital, Rabat, Morocco, between January 1 and December 31, 2022. The study population was divided into two groups: 19 patients with type 1 diabetes (13 females and six males, with an age range of 20-70 years) and 72 patients with type 2 diabetes (52 females and 20 males, with an age range of 40-71 years). Hemoglobin (HbA1c) levels were determined with high-performance liquid chromatography (Hb-HPLC) analyzer from blood samples collected in EDTA tubes, and anti-thyroid antibodies (anti-TPO and/or anti-TG) were measured by chemiluminescent microparticle immunoassays (CMIA) in human serum using the ALINITY analyzer. Results Among type 1 diabetic patients, 42.1% (n = 8) were positive for anti-TPO and anti-TG antibodies, while 31.5% (n = 6) were positive only for anti-TPO antibodies. Among type 2 diabetic patients, 15.2% (n = 11) were positive only for anti-TPO antibodies, while 20.8% (n = 15) were positive for anti-TPO and/or anti-TG antibodies. The prevalence of anti-thyroid antibodies was higher in females, consistent with other studies. This could be linked to the involvement of autoimmune processes in the development of thyroid dysfunction in type 2 diabetics. Conclusions Testing for anti-thyroid antibodies in diabetic patients and their relatives helps detect subclinical conditions, which could later manifest as biological and clinical deficiencies, guiding monitoring parameters.
RESUMO
BACKGROUND: Wound healing is among the frequent illnesses that affects the skin, and therefore, the screening of natural preparation to treat skin burn is important. In Morocco, Cynara humilis is a Moroccan medicinal plant widely used for the treatment of skin burn. OBJECTIVES: The aim of this study was to investigate the safety of C. humilis and its wound healing potential against skin burn. METHODS: In this work, C. humilis was selected based on an ethnopharmacological survey. As revealed by traditional medicine, C. humilis powder extract (CHPE) was used to test wound healing effects. Furthermore, to assure the safety of this powder, acute and subchronic dermal toxicities were investigated on animal models. RESULTS: The oral acute toxicity test of CHPE did not show mortality in treated rats (LD50 >2000 mg/kg). Moreover, in the acute dermal toxicity, CHPE at 5 g/kg did not induce clinical signs observed during the observation period of 48 h. In the subchronic toxicity test, CHPE did not cause significant abnormalities in the physiological parameters and pathological changes in the major organs of the rats. Body weight evolution and macroscopic analysis of skin burn showed CHPE exhibited important wound healing effects in a time-dependent manner. CHPE reduced significantly wound surface (6.93 ± 0.25 cm2 ) compared with the SDA group (8.30 ± 0.37 cm2 ) and the no-treated group (10.05 ± 0.28 cm2 ). Moreover, the retention rate was increased importantly after the treatment with CHPE (61.66 ± 1.42%) compared with the SDA-treated group (53.57% ± 2.83%) and the no-treated group control animals (43.34% ± 1.27%). CONCLUSION: These results were confirmed by a histological evaluation, which showed that CHPE increased the neovascularization, the collagen deposition, and the re-epithelialization. The findings of this work suggest that CHPE could be a promising source for developing drugs against skin burn.